Is NCNA or NKTR more undervalued in 2026?

CirclFi compares NuCana plc (NCNA) and Nektar Therapeutics (NKTR) using 13 institutional-grade valuation models. NCNA has a Quality of Company score of 1.7/10 while NKTR scores 5.9/10.

Which is a better buy — NCNA or NKTR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NCNA and NKTR valuations compare?

NCNA at $2.27 and NKTR at $65.01 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NCNA vs NKTR Valuation Comparison 2026 — Intrinsic Value Analysis

NCNA

Biotechnology

NuCana plc

Quality

1.7

out of 10

Value Trap

—

Price

$2.27

Last close

Models

6/13

Active

NKTR

Biotechnology

Nektar Therapeutics

Quality

5.9

out of 10

Value Trap

SAFE

Price

$65.01

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	NCNA Fair Value	NCNA Upside	NKTR Fair Value	NKTR Upside
Bayesian DCF	Intrinsic	$0.60	-73.5%	$18.82	-71.1%
Earnings Power Value	Intrinsic	—	—	$5.62	-93.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.98	+85.3%	$9.48	-85.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NCNA vs NKTR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NCNA vs NKTR — Which Stock Is More Undervalued?

NKTR scores higher with a 5.9/10 quality rating vs NCNA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NuCana plc (NCNA) and Nektar Therapeutics (NKTR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NCNA currently trades at $2.27 with a QOC of 1.7/10, while NKTR trades at $65.01 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).